AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32315537
Drug: Antidepressant Treatment
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Treatment Record (ATR) classification level 2
Trial: 32315537
Drug: Antidepressant Treatment
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Treatment Record (ATR) classification level ≥3
Trial: 32315537
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with serotonin norepinephrine reuptake inhibitors (SNRIs)
Trial: 32315537
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with dopamine norepinephrine reuptake inhibitors (DNRIs)
Trial: 32315537
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with mixed dopamine serotonin receptor antagonists
Trial: 35707522
Drug: Integrative Acupuncture
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative Acupuncture and Moxibustion (iAM) treatment
Trial: 35707522
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg once a day)
Trial: 35707522
Drug: Active/sham iAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active/sham iAM treatment (three times per week)
Trial: 34283799
Drug: Classical music
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical music played during treatment
Trial: 34283799
Drug: No music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No music played during treatment
Trial: 34551581
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (LB) - 40 ml 0.125% SB plus 20 ml of LB
Trial: 33218524
Drug: Daily aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily aerobic walking exercise (DAWE)
Trial: 32166831
Drug: Clonidine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (3 µg/kg intravenous bolus)
Trial: 32173808
Drug: Ropivacaine (R)
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine (R) 2mg/kg with ropivacaine: 4.75 mg/ml in wound infiltration (WI)
Trial: 33435969
Drug: Three-part equal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-part equal incentive for home testing, attendance of weekly telephone education classes, and HbA1c reduction at 3 months (Group 3)
Trial: 35927806
Drug: Active 10Hz
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active 10Hz rTMS (n=63) in CC homozygotes
Trial: 36082412
Drug: Light Dark
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light Dark Therapy (LDT)
Trial: 33002437
Drug: Salvage radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiotherapy (64 Gy in 32 fractions triggered by PSA of 0.20 ng/mL or more)
Trial: 34848508
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow rhinothermy (rNHF) - 100% humidified air delivered at 35 L/min and 41°C for 2 hours daily for 5 days
Trial: 34848508
Drug: Sham rhinothermy
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rhinothermy - 100% humidified air delivered at 10 L/min and 31°C for 10 min daily for 5 days
Trial: 34587648
Drug: L-NMMA (NOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (NOS inhibitor)
Trial: 33675264
Drug: Hemp-based nutraceutical
RxNorm normalized name: hemp
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp-based nutraceutical product (Gs Formula; GF) at 160 g/day (LO)
Trial: 33675264
Drug: Hemp-based nutraceutical
RxNorm normalized name: hemp
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp-based nutraceutical product (Gs Formula; GF) at 480 g/day (HI)
Trial: 33675264
Drug: Hemp-based nutraceutical
RxNorm normalized name: hemp
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp-based nutraceutical product (Gs Formula; GF) at 0 g/day (CON)
Trial: 32791704
Drug: Sogyeonghwalhyeol-tang (SGHH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sogyeonghwalhyeol-tang (SGHH) with Chuna manual therapy (CMT)
Trial: 32791704
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Chuna manual therapy (CMT)
Trial: 34900185
Drug: Chrysanthemum extract
RxNorm normalized name: Chrysanthemum indicum top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chrysanthemum extract 400 mg/day (200 mg/day, twice/day)
Trial: 36459070
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (neurodevelopmental treatment and talocrural joint MWM)
Trial: 33267762
Drug: Intravitreal Dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Dexamethasone implant (IVD) 0.7 mg, single dose
Trial: 33267762
Drug: Intravitreal Ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Ranibizumab injection (IVR) 0.3 mg, 3 doses (monthly)
Trial: 33267762
Drug: Intravitreal Dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Dexamethasone implant (IVD)
Trial: 33267762
Drug: Intravitreal Ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Ranibizumab injection (IVR)
Trial: 33631355
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg/6 months)
Trial: 32282491
Drug: Aromatherapy (lavender
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy (lavender oil) inhalation administered half hour before sleep every day for a month.
Trial: 32282491
Drug: No administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No administration applied to the control group.
Trial: 36422204
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone (1 mg/mL)
Trial: 36422204
Drug: Topical bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bromfenac (0.9 mg/mL)
Trial: 32066489
Drug: Ticagrelor (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (loading dose 180 mg, maintenance dose 90 mg bid)
Trial: 32066489
Drug: Clopidogrel (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (loading dose 600 mg, maintenance dose 75 mg)
Trial: 33655799
Drug: Weekly aerobic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly aerobic exercises associated with nutritional counseling
Trial: 32271583
Drug: Ultraviolet-Ozone (UVO)
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraviolet-Ozone (UVO) treatment applied to drug-coated balloons (DCBs) with urea-paclitaxel coating.
Trial: 32271583
Drug: Standard drug-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug-coated balloons (DCBs) without UVO treatment.
Trial: 34587702
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose red yeast rice (200 mg/day) containing 2 mg monacolin K
Trial: 36064438
Drug: AutoKinetics dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AutoKinetics dosing for ciprofloxacin
Trial: 36064438
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing for ciprofloxacin (Control)
Trial: 34265777
Drug: Attention Control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Control followed by Cognitive Processing Therapy (CPT)
Trial: 34712679
Drug: Jinhua Qinggan
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jinhua Qinggan granules combined with antiviral drugs
Trial: 34712679
Drug: Antiviral drugs
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs alone (Western medicine group)
Trial: 36013168
Drug: Lung ultrasound-guided
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung ultrasound-guided therapy (LUS)
Trial: 36086764
Drug: Remifentanil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.0 ng/mL with midazolam
Trial: 36086764
Drug: Remifentanil 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2.0 ng/mL with midazolam
Trial: 33181560
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Cannula (HFNC) with a flow rate of 2 L kg‐1 min‐1
Trial: 32170769
Drug: Bortezomib consolidation
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib consolidation (BC) - 1.3 mg/m2 IV days 1, 4, 8, 11 of a 3-week cycle for four cycles
Trial: 32170769
Drug: Bortezomib maintenance
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib maintenance (BM) - 1.6 mg/m2 IV once weekly × 4 every 8 weeks for 18 months
Trial: 33466606
Drug: Percussion Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percussion Therapy (PT)
Trial: 32823974
Drug: Multivitamin and
RxNorm normalized name: Multivitamin and Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin and mineral supplement (Redoxon® VI, Singapore) taken daily for 12 weeks
Trial: 32823974
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (inactive) taken daily for 12 weeks
Trial: 32979077
Drug: 300 mg/d
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/d DHA for 6 months
Trial: 32532761
Drug: Micropulse laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micropulse laser therapy (MLT)
Trial: 33444588
Drug: Marine n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine n-3 fatty acid (1 g/d)
Trial: 33413588
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 7.5-20 mg/kg
Trial: 33683325
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of high-dose amoxicillin followed by 5 days of placebo
Trial: 33683325
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of high-dose amoxicillin followed by a different formulation of 5 days of high-dose amoxicillin
Trial: 32388274
Drug: 400 g
RxNorm normalized name: Ambi 60 PSE-400 GFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 g of cod fillets per week
Trial: 35170539
Drug: Adjuvant steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant steroid therapy (10-12 weeks)
Trial: 35170539
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine postoperative treatment)
Trial: 34798060
Drug: Cagrilintide 0.3-4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide 0.3-4.5 mg
Trial: 34798060
Drug: Cagrilintide 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide 4.5 mg
Trial: 34233667
Drug: Antibiotic sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic sensitivity to Cefazolin
Trial: 34233667
Drug: Antibiotic sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic sensitivity to Tetracycline
Trial: 35388666
Drug: Oral tebipenem
RxNorm normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tebipenem pivoxil hydrobromide (600 mg every 8 hours)
Trial: 35388666
Drug: Intravenous ertapenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ertapenem (1 g every 24 hours)
Trial: 35388666
Drug: Oral tebipenem
RxNorm normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tebipenem pivoxil hydrobromide
Trial: 35388666
Drug: Intravenous ertapenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ertapenem
Trial: 36145064
Drug: Fava bean
RxNorm normalized name: Fava Bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fava bean protein (FBP) 0.33 g·kg‐1
Trial: 32424935
Drug: 1.8 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg/d liraglutide
Trial: 35640182
Drug: Combined orthodonto-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined orthodonto-surgical treatment
Trial: 32579811
Drug: Allopurinol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100 to 300 mg daily)
Trial: 35506425
Drug: Extra time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra time with alcohol and drug nurses
Trial: 33863276
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-i)
Trial: 36333742
Drug: music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: music therapy activities
Trial: 35545225
Drug: Rapid Intermittent
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Intermittent Bolus (RIB) of electrolyte-free solution for 1 hour
Trial: 35545225
Drug: Slow Continuous
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow Continuous Infusion (SCI) of electrolyte-free solution continuously
Trial: 36203215
Drug: Family-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive behavioural therapy (FCBT)
Trial: 33477443
Drug: Mohana Choorna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mohana Choorna (Ayurvedic herbal preparation)
Trial: 33322022
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of epigallocatechin gallate (EGCG) and 60 mL of coconut oil daily for 4 months
Trial: 32150661
Drug: Everolimus at
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus at a dose of 6 mg/m2
Trial: 34157162
Drug: FCL combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCL combined with intradermal injection of plasma gel
Trial: 34157162
Drug: FCL combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCL combined with topical application of plasma gel
Trial: 34157162
Drug: FCL monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCL monotherapy
Trial: 39491396
Drug: Darolutamide 600
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide 600 mg twice daily
Trial: 36081217
Drug: Fluoxetine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine for 26 weeks
Trial: 35772622
Drug: Antimicrobial Photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial Photodynamic Therapy with methylene blue (300 µmol/L)
Trial: 35772622
Drug: Antimicrobial Photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial Photodynamic Therapy with curcumin (8 µmol/L)
Trial: 34607196
Drug: Neuroaspis PLP10™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroaspis PLP10™ (20 ml once daily for 30 months)
Trial: 34607196
Drug: Control (pure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pure virgin olive oil, 20 ml once daily for 30 months)
Trial: 35172891
Drug: Intravenous imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous imatinib mesylate 200 mg bis in die (b.i.d.) for 7 days
Trial: 35172891
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusion for 7 days
Trial: 32696258
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg/kg/h IV infusion for 24 h)
Trial: 32696258
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 μg/kg/h IV infusion for 24 h)
Trial: 35183168
Drug: Subsidized eyeglasses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsidized eyeglasses provided to myopic children in treatment schools
Trial: 35183168
Drug: Prescription information
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription information provided without subsidized eyeglasses in control schools
Trial: 32727831
Drug: Sequential Xpert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Xpert followed by LAM
Trial: 32727831
Drug: Concurrent testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent testing with LAM + Xpert
Trial: 32727831
Drug: Cost per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost per TB case diagnosed for sequential and concurrent strategies
Trial: 34905482
Drug: Low-intensity magnetic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity magnetic stimulation (LIMS) plus standard pharmacological treatment
Trial: 34534858
Drug: CBT-T (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-T (Cognitive Behaviour Therapy emphasizing early behaviour change and body image improvement)
Trial: 34534858
Drug: CBTm (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBTm (Cognitive Behaviour Therapy including motivational work and no body image content)
Trial: 32495666
Drug: Permethrin 5%
RxNorm normalized name: PERMETHRIN 5% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 5% cream applied on two occasions within a one-week interval (Group A)
Trial: 32495666
Drug: Intensive application
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive application of permethrin 5% cream (Group B)
Trial: 36364742
Drug: NO3−/NO2− supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO3−/NO2− supplementation (beetroot juice containing 250 mg nitrate and 20 mg nitrite/day)
Trial: 32562684
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg PD01A
Trial: 32562684
Drug: 75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 μg PD01A
Trial: 32562684
Drug: Booster immunisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster immunisation (75 μg)
Trial: 32562684
Drug: Systemic treatment-related
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment-related adverse events
Trial: 32568400
Drug: Nocturnal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal oxygen therapy (NOT) administered at 3 L/min by nasal cannula during nights at 2048 m
Trial: 32568400
Drug: Placebo (room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (room air) administered during nights at 2048 m
Trial: 35902817
Drug: SARS‐CoV‐2 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS‐CoV‐2 vaccines (first two licensed in Switzerland)
Trial: 34974277
Drug: Kinesio Taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio Taping (KT) plus Oral-Motor Training (OMT)
Trial: 34974277
Drug: Sham Taping
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Taping plus Oral-Motor Training (OMT)
Trial: 33151187
Drug: Both TR
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TR and free-hand implants
Trial: 33762428
Drug: Epigallocatechin‐3‐gallate (EGCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epigallocatechin‐3‐gallate (EGCG) 800 mg daily for 18 months
Trial: 34951974
Drug: IDA (Intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDA (Intradermal Adaptor)
Trial: 33069301
Drug: Cytisine (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisine (9 mg on day 0, gradually reduced to 1.5 mg by day 25)
Trial: 36195897
Drug: Social norm
RxNorm normalized name: K Norm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social norm feedback on antibiotic prescribing
Trial: 36195897
Drug: Social norm
RxNorm normalized name: K Norm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social norm feedback plus online peer-moderated training on rational antibiotic prescribing, communication strategies, and sustainable behavior change
Trial: 34830709
Drug: Internal conical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal conical connection implants
Trial: 34830709
Drug: Internal hexagonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal hexagonal connection implants
Trial: 35426033
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg capsule for 14 days during each chemotherapy cycle
Trial: 35426033
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14 days during each chemotherapy cycle